ClinicalTrialsFinder
RecruitingNot ApplicableNCT07366099

Al18F-NOTA-LM3 PET/CT in Patients With TIO

Application of Al18F-NOTA-LM3 PET/CT in the Diagnosis and Evaluation of Tumor-Induced Osteomalacia

Sponsor

Peking Union Medical College Hospital

Enrollment

40 participants

Start Date

Mar 30, 2023

Study Type

INTERVENTIONAL

Conditions

Tumor-Induced Osteomalacia

Summary

This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

  • Patients aged 18 to 80 years.
  • Suspected or confirmed TIO patients.

Exclusion Criteria4

  • Combined with other types of tumors.
  • Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min).
  • Pregnant or breast-feeding women.
  • Inability to perform PET/CT scans.
Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDiagnostic Test: Al18F-NOTA-LM3

Al18F-NOTA-LM3 will be injected into the patients. Patients will undergo a whole-body PET/CT scan 60-120 minutes after injection.

DRUGDiagnostic Test: 68Ga-DOTATATE

68Ga-DOTATATE will be injected into the patients. Patients will undergo a whole-body PET/CT scan 40-60 minutes after injection.

Locations(1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07366099